Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IPCI has two products ready to sell without a contract with any distributor. Then they have Seroquel with too low interest from MNK. On top of that Focalin deal with PAR gives almost nothing to IPCI.
So - there is enough potential to make this much bigger.
What IPCI should have now, it an own sales organisation. Even if it would cover only a couple states to start with, it would perform much better than present arrangement where Keppra and Gluco are not sold at all, Seroquel is sold with extremely low interest from MNK and on top of that IPCI will get only a fraction of MNK sales for it.
With own sales organisation IPCI could even make a bit aggressive pricing policy to make this fly.
Partnering the rest of ANDAs now would be a disaster if the partner performes like MNK does with Seroquel. As we know, there are three pending ANDAs without partnering now. It would make a great potential if IPCI had an own sales organisation.
Partnerin would be the only way to go if IPCI had only one product, but in this situation it's not.
You can find the numbers I gove in the previous message here:
https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm
The sales of some companies without XR version approved can be made by some kind of sales collaboration, but definitely Fred gove us XR version sales.
Only big question is, why MNK can make only 1-2% the sales Accord and Lupin does. This is the main question now. Can MNK and IPCI do something about it.
Fred,
Can you take Seroquel ER sales here for comparison?
Does anyone know what's desvenlafaxin situation? Has IPCI completed all needed tests?